Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.53 |
| ▸ | MMP13 | P45452 | 19/20 | 0.53 |
| ▸ | MMP1 | P03956 | 16/20 | 0.53 |
| ▸ | MMP9 | P14780 | 16/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559431 | 0.92 | ADAM17 (0.54) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6558782 | 0.90 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6559410 | 0.81 | ADAM17 (0.51) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6811149 | 0.79 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6810945 | 0.79 | ADAM17 (0.64) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6815391 | 0.77 | ADAM17 (0.63) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6293370 | 0.75 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6559764 | 0.75 | ADAM17 (0.51) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3940134 | 0.74 | ADAM17 (0.61) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6290522 | 0.72 | ADAM17 (0.84) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147102-B1 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | WYETH HOLDINGS CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1147102-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | disclosed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | TNF, SI, MMP12 | ADAM17 74/4885MMP13 84/4885MMP1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.